Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "Regimen"

194 News Found

AstraZeneca Pharma India receives permission for sale and distribution of Trastuzumab deruxtecan
News | May 04, 2023

AstraZeneca Pharma India receives permission for sale and distribution of Trastuzumab deruxtecan

The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India


USFDA puts on hold Sun Pharma trials on dermatological drug
Drug Approval | May 04, 2023

USFDA puts on hold Sun Pharma trials on dermatological drug

Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose


FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer
Drug Approval | April 04, 2023

FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients


Lupin Digital Health reveals results of digital therapeutics study with ACS patients
Digitisation | March 18, 2023

Lupin Digital Health reveals results of digital therapeutics study with ACS patients

The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform


Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
Drug Approval | February 20, 2023

Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States


FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Drug Approval | January 30, 2023

FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer

Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US


Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial
News | December 13, 2022

Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial

The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama


Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Diagnostic Center | December 12, 2022

Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes


Jemperli RUBY phase III trial met its primary endpoint
Diagnostic Center | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival